Strategic Growth Sever Pharma Solutions is expanding leadership with a new General Counsel and VP of Quality, signaling a structured governance and quality-focused growth trajectory that can be leveraged to position expanded CDMO collaborations, compliance-driven projects, and larger-scale GMP manufacturing engagements.

Global Manufacturing With facilities in Malmö and Putnam and a specialization in controlled-release and high-potent drug delivery, target opportunities exist in international CDMO partnerships for complex formulations, regulatory-compliant scale-up, and cross-border supply for clinical and commercial needs.

Regulated Expertise Strong emphasis on GMP and cGMP analytics for oral tablets, transdermal films, implants, and drug-eluting devices presents a compelling case for clients seeking robust development-to-manufacturing pipelines, including feasibility, process development, and validation services.

Strategic Collaborations Recent activity with Silo Pharma and participation in industry events like DCAT Week 2025 indicate a proactive pursuit of partnerships in novel delivery modalities, creating openings for co-development, licensing, or long-term manufacturing agreements.

Financial Target Revenue in the mid-market range and a footprint of 2–10 employees suggest high-margin opportunities for scalable, tightly scoped programs, as well as potential upsell into larger CDMO engagements as client programs mature.